Lauroyl-gemcitabine loaded lipid nanocapsules for the treatment of metastases in mediastinal lymph nodes

! "

$

% &

' ( )

* + ' , +

!" # $%%&& '

# () ' (( *+ , ' *-

. / 0 -1 ( ' ( ( -" (2 32 4 -3 5 2

3 5 2 66 78 & 9 0 *

& " ( '4 2 4 ! (( 3 : 2 ( '4 : ( '4 / 0 " 0 (

' # $%%&& # *

- .&/ 01 %.-/

' 2 ( ' - ( ( 4 2 ; ( < = ( . &>* 1 ' (( ((( ' < ! !> 8 4 ( 2 '( + ((4 8? ; 2 2 --

2 0 ( 2 ' 4 2 04 2 2 04* # 0 ! ! 2 0 ( 0 ( ( (4 02 < . ' > 2 ( (( ' 0( ( 4 + 4 ( '

< ' @> <# = ( . .>* 0 2 ' ( 2 - ' 2 (4 02 +4 2 ( 4 A ( + 4 ' (

< !" 1 / ( . .>*

0 0 ( < !> ( ; 2 ( 4( - ' + <= ! .> 2 + ( 0 2 + ( 4 - 24 ' (+4 0 ( +(4 < 1 B ( . &>* 32 (

+ ( ' (+4 + < > 0 < - ( > - < > * 32 0 0 - 2 4 2 0 (4 2 (4 02 ( 2 -- 4 - 2

; 4 2 ! ! ( ; 2 2 2 0 ' - - 2 0 4 0( 2 ( ' - * 32 ( < 4 ( 0 2 0 A 4> - 2 ;

( 2 ' (+4 0 +4 ; ( ' *

HN

O Z-Ave

(nm) PdI -Pot^c

(mV) 21 &/ 3 / 0-4- 0 * %-.2+- 5 / 20 0 -,-0 2 / %2,61 6

/ (

,2.- . - 3 ,( / * / 1 6 .26.2.-% ,& % - -%2 / 0

+ + -/ / ! 2 (24 -

C < ( > -/ / ! 0 < 0 ( = ! .>

+-/ 0-6.&-+1 .-/ - ( 2 .( 3 2 0 .1 / & + 2&- * -%

N N O O OH HO

F HN

F

(nm) PdI

(mV) Non-loaded LNC (iv) 68 ± 3 0.08 ± 0.02 -8 ± 3 Non-loaded LNC (sc) 67 ± 2 0.07 ± 0.01 -10 ± 5 LNC Gem-C12 (sc) 53± 2 0.07 ± 0.01 -7 ± 4 LNC Gem-C12 (iv) 53 ± 1 0.04 ± 0.01 -7 ± 3 DiD-Gem-C12 loaded LNC (sc) 56 ± 2 0.04 ± 0.02 -5 ± 2 DiD-non-loaded LNC (iv) 55 ± 2 0.06 ± 0.02 -7 ± 4

4( - = +

<= ! .> ; 00 2 (0

0 ( < !> - '

- ( 0 24 ' (

; + ; 2 !

*

:24 2 ( 2 -( ( ! -

C < D&E F / >*

/ (

! (

C C # 1 B ( . $

7 8⁹

0 ( 4 0( 0 0 <- #>*

< > ' <0 5 ; 2

0 (4> - 4 . 0 ' - E

2 ( ' ( ( -( ' + ' 2 $$ & < !>*

! / ! 6 - 2 ( < ² 4 0 ' - >

- ((0 4 ( ' *

( ( 0(

(( (4 02 ; + ; 2 / /

( ! 0 (4 ( *

/ / = ! . ( ! ' ( -

+ (4 ( ( A ( (4

2 (4 02 ( 2 C

0 4 ( ; 4 A0 *

2 +

C < ( > -/ / ! 0 < 0 ( = ! .>

< > + C <+ 2 2 5> - / / !

24 ' (<8? = ! .G + - ; G; > <! / >* - -

2 -( ' ( - 2 ( 0( ' (

A (( 4 ( + 2 ( (4 02 < > ' -(

' < ' > !

< $ 7 $7 % && 2>* < D8 ±/ >*

DID visualization mode Pp IX visualization mode

scadministration scadministration

0 4 ( ; 4 A0 *

H 2 + ' ! / ! 6 / / !

; +( 2 ( ' - 2 2

- C * 1 2 4 / / !

+4 ( (

( ((4 02 *

+ 0

@ (I - ( ' - 2 4 8 - 0(

- (( ; ' ( -$ 'G5' -8 ( (

- ! ( ; 2 / / + (4 ( <; 2

= ! .> ' < > :0 J < > / / (I E (4

( <; 2 = ! .> ' <!> :0 J </ > / / (I

' ! 4 * ; 0 2 ( (I -

DID visualization mode Pp IX visualization mode ivadministration

ivadministration

+%

: ; <

&+%

: ; <

( *+

: ; <

( %.

:= <

, . : ; <

6 *. F * %*7 F *& 8* F *& $6 F $ % F 8

* *. F * %*. F *& $* F *$ $8 F 9> ? @# A

* % *& F *. %* F * $ F $8 F . .68 F &

% * F *& %*7 F *. 8* F *& $6*6 F *% $ 8 F $$

% * % * $ F * & 7*% F *. &*6 F *& $&* F *% .7$ F .$

% *$ F * %*$ F *6 $ F $ F & $8& F . 2 .-.1 / & 44-%2%3 2 0 ./ &2 % / 4 .& 2. .6

' ! 4 * ; 0 2 ( (I -

((4 02 2 0 * ivadministration DID visualization mode

% * % *. F * %*$ F *8 $*8 F *7 $8 F . .7 F 7&

262.

:1 -; <

2 2.

:1 -; <

,( 2 :1 -; <

% : ; <

6 &7 F 8 .$ F 7 $ F 7 *7 F *$

* %7 F .6 .6 F . .% F 6 & F &

* % 8. F %8 .& F 7 BC ? ## A . F

% 66 F . .. F $ &% F $ *6 F *8

% * % 7. F . 7 F 6 $& F $ & F .

% 77 F 8. .$ F % F 8 . F

% * % 86 F 8. &. F . F $ F &

' - ( (<0 K * 8 ( ' 5 > ; 2 ; 2 ((' + 0 ( < ; 2 '>*

" ; 2 ; ' - -- + ; 2 ( - ' 0 +4 ' + ' ( - 2 -

32 L 0( ( 2 ; '2 ( - < D 0 ' 0> ' - ; 2 $$ & (( - ' +

< ( -$ 'G5' ( ( ' + 24 2( >*

%/ % 1 6-/

32 (0 0 ( ( ; 2 (0 02 ( - ' + ; +( ' 2 (4 02 0 - ((4 2 ((4 02

0( 4 ' ( -- 4 2 ( 4 ' + 2 (4 02 ' 0 ( ( (; 2 2 ( - ;

; 5 0 2 ; 5 - 2 '* ! ( ; 2 = ! . ( 4 ( 00

(5 2 ( 4 ' + * 32 ( - 2 ; ( (4 2 ' + '2 +4 - ( -' + *

2% / 0* .6

32 ; 5 2 + (I ; 2 2 2 0 '

B :" 1 3 = - ((4 00 +4 3

% +4 2 ' : 4 ( *

% * % 86 F 8. &. F . F $ F &

" ; 2 ; ' - -- + ; 2 ( - ' 0 +4 ' + ' ( - 2 -

* 32 ; '2 ( - 2 -- ' 0 ( ' 2 A0 ; 2 2 + (I '

2 0 *

3 ; 2 0 ( = + 0 ' - <0 K * 8 L 5 ( H (( > -0( ( (5 (

02 02 * -- ; - 0( + 2 ( 0 0( +( ; 2 = ! . ;

0 ( ! ' ( - 2 - *

( ' ( (4 0( +( -- ' 0 * H !) 0( ' ( 4

!) +( (( " = ) 2 '( + " !3) 2 : 3) 0( ( 3) 0

- 3) ( - :" L) (5 ( 02 02 * < D8E F /

M) 0 K * 8 L 5 (( H (( / N >*